DK3356313T3 - 2-perfluorhexyloktan til oftalmisk indgivelse - Google Patents

2-perfluorhexyloktan til oftalmisk indgivelse Download PDF

Info

Publication number
DK3356313T3
DK3356313T3 DK16775673.3T DK16775673T DK3356313T3 DK 3356313 T3 DK3356313 T3 DK 3356313T3 DK 16775673 T DK16775673 T DK 16775673T DK 3356313 T3 DK3356313 T3 DK 3356313T3
Authority
DK
Denmark
Prior art keywords
perfluorohexyloctane
ophthalmic administration
ophthalmic
administration
Prior art date
Application number
DK16775673.3T
Other languages
Danish (da)
English (en)
Inventor
Dieter Scherer
Ralf Grillenberger
Frank LÖSCHER
Hartmut Voss
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Application granted granted Critical
Publication of DK3356313T3 publication Critical patent/DK3356313T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C07C17/266—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00—Acyclic saturated compounds containing halogen atoms
    • C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16775673.3T 2015-09-30 2016-09-29 2-perfluorhexyloktan til oftalmisk indgivelse DK3356313T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15187760 2015-09-30
EP15192429 2015-10-30
PCT/EP2016/073262 WO2017055453A1 (en) 2015-09-30 2016-09-29 Semifluorinated compounds for ophthalmic administration

Publications (1)

Publication Number Publication Date
DK3356313T3 true DK3356313T3 (da) 2020-07-20

Family

ID=57068093

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16775673.3T DK3356313T3 (da) 2015-09-30 2016-09-29 2-perfluorhexyloktan til oftalmisk indgivelse
DK20172665.0T DK3722274T3 (da) 2015-09-30 2016-09-29 2-perfluorbutylpentan til oftalmisk indgivelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK20172665.0T DK3722274T3 (da) 2015-09-30 2016-09-29 2-perfluorbutylpentan til oftalmisk indgivelse

Country Status (14)

Country Link
US (2) US11154513B2 (https=)
EP (3) EP4234523A1 (https=)
JP (2) JP6642935B2 (https=)
KR (2) KR102584063B1 (https=)
CN (4) CN110693825B (https=)
AU (3) AU2016329261B2 (https=)
CA (1) CA2998269C (https=)
DE (1) DE202016008739U1 (https=)
DK (2) DK3356313T3 (https=)
ES (2) ES2953837T3 (https=)
MX (2) MX2018003781A (https=)
PL (2) PL3722274T3 (https=)
PT (1) PT3356313T (https=)
WO (1) WO2017055453A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
DK3181119T3 (da) 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
MX2018003781A (es) * 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) * 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020064556A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Topical sunscreen formulation
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
CA3233317A1 (en) * 2024-03-26 2025-10-30 Apotex Inc. Solid complexes comprising urea and semifluorinated alkanes

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
DK0983037T3 (da) 1998-02-09 2003-09-01 Macrochem Corp Fungicid neglelak
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
EP1152749B1 (en) 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2000054588A1 (en) 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
WO2002089849A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
DE60223694T2 (de) 2001-09-04 2008-10-30 Trommsdorff Gmbh & Co. Kg Arzneimittel Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP1663148A2 (en) 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
JP2007511616A (ja) 2003-11-19 2007-05-10 バーンズ−ジューイッシュ ホスピタル 増強された薬物送達
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005099718A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) 2004-06-08 2008-01-24 オキュラリス ファーマ， インコーポレイテッド 疎水性眼用組成物および使用方法
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
KR20080043793A (ko) 2005-08-05 2008-05-19 바라트 쎄럼스 앤드 백신스 리미티드 방부 효능을 갖는 정맥 프로포폴 에멀젼 조성물
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005055811A1 (de) * 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008060359A2 (en) 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
WO2008070490A2 (en) 2006-11-28 2008-06-12 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2089282B1 (en) 2006-12-07 2014-01-08 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
EP2110126B9 (de) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
WO2010062394A2 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
CN102802619A (zh) 2009-06-25 2012-11-28 狮王株式会社 眼科用组合物
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
SI2387391T1 (sl) 2009-07-24 2017-04-26 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Postopek za pripravo tekočega sestavka, ki se nanaša na kožo v obliki pene, in sestavka, ki se lahko nanaša topično
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
DE102010022567A1 (de) * 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) * 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2661280T3 (en) 2011-01-04 2019-03-04 Novaliq Gmbh O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
KR101773648B1 (ko) 2011-05-25 2017-08-31 노바리크 게엠베하 조갑에 투여를 위한 제약학적 조성물
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
KR101989648B1 (ko) 2012-01-23 2019-06-14 노바리크 게엠베하 부분불소화 알칸에 기초한 안정화된 단백질 조성물
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
DK3181119T3 (da) * 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN113679697A (zh) * 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
US9265809B2 (en) 2013-10-09 2016-02-23 Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MX376125B (es) 2014-03-31 2025-03-07 Amcor Rigid Plastics Usa Llc Recipiente de liberacion controlada.
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
JP6660939B2 (ja) 2014-08-13 2020-03-11 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 点眼剤からの保存剤除去
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN108348777B (zh) * 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
MX2018003781A (es) * 2015-09-30 2018-09-12 Novaliq Gmbh Compuestos semifluorados para administracion oftalmica.
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
EP3558308A1 (en) 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco

Also Published As

Publication number Publication date
DE202016008739U1 (de) 2019-04-29
MX2020001408A (es) 2022-04-13
CN108349855A (zh) 2018-07-31
CN110693825A (zh) 2020-01-17
WO2017055453A1 (en) 2017-04-06
US11154513B2 (en) 2021-10-26
EP3356313A1 (en) 2018-08-08
KR20180059823A (ko) 2018-06-05
ES2953837T3 (es) 2023-11-16
US20170087101A1 (en) 2017-03-30
JP2018529693A (ja) 2018-10-11
JP2020073551A (ja) 2020-05-14
EP3722274A1 (en) 2020-10-14
AU2020205239B9 (en) 2021-10-28
AU2016329261A1 (en) 2018-04-12
EP3356313B1 (en) 2020-05-06
CA2998269A1 (en) 2017-04-06
CN113662928B (zh) 2026-03-24
EP3722274B1 (en) 2023-06-07
KR102584063B1 (ko) 2023-09-27
AU2022200366B2 (en) 2023-11-09
CA2998269C (en) 2021-03-23
PL3356313T3 (pl) 2020-11-16
CN113662928A (zh) 2021-11-19
KR20200106097A (ko) 2020-09-10
AU2020205239B2 (en) 2021-10-21
CN113662929A (zh) 2021-11-19
DK3722274T3 (da) 2023-09-11
ES2803248T3 (es) 2021-01-25
MX391587B (es) 2025-03-21
AU2022200366A1 (en) 2022-02-17
EP4234523A1 (en) 2023-08-30
AU2020205239A1 (en) 2020-07-30
MX2018003781A (es) 2018-09-12
US20210315832A1 (en) 2021-10-14
PL3722274T3 (pl) 2023-12-04
CN110693825B (zh) 2022-03-08
HK1257182A1 (en) 2019-10-18
JP7050741B2 (ja) 2022-04-08
CN108349855B (zh) 2021-07-20
PT3356313T (pt) 2020-07-13
KR102154415B1 (ko) 2020-09-10
AU2016329261B2 (en) 2020-05-07
JP6642935B2 (ja) 2020-02-12

Similar Documents

Publication Publication Date Title
DK3356313T3 (da) 2-perfluorhexyloktan til oftalmisk indgivelse
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3072835T3 (da) Fremgangsmåde til fremføring
EP3374114A4 (en) WORKBENCH
EP3344318A4 (en) Patient interfaces
BR112016030368A2 (pt) composição oftálmica
DK3265421T3 (da) Doseringssystem
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
SI4070787T1 (sl) Farmacevtske formulacije
DK3380139T3 (da) Medikamentadministrationsanordning
DK3125898T3 (da) Farmakofor til trail-induktion
DK3199161T3 (da) Farmaceutisk præparat
DK3171701T3 (da) Infusionsanlæg
DK3348260T3 (da) Farmaceutisk tramadol-sammensætning til oftalmisk anvendelse
EP3246047C0 (en) COMBINATION MEDICATION
EP3437644A4 (en) MEDICINE
KR20180084810A (ko) 정제 세트
EP3527216A4 (en) Medicine
DK3349825T3 (da) Lægemiddeladministrationsanordning
DK3280447T3 (da) Farmaceutiske formuleringer
EP3334447A4 (en) CCK2R-drug conjugates
DK3349827T3 (da) Lægemiddeladministrationsanordning
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
EP4233950C0 (en) NASAL ADMINISTRATION
EP3372264A4 (en) SYRINGE